• Policy
• Alvogen’s Alymsys reimbursed...compete with Avastin similar
• by Lee, Tak-Sun Oct 12, 2022 05:50am

• Policy
• Two companies' Ticagrelor can be reimbursed
• by Lee, Tak-Sun Oct 7, 2022 06:04am

• Policy
• Innovative pharmaceutical companies' new drug tx
• by Lee, Jeong-Hwan Oct 7, 2022 06:03am

• Policy
• The incidence of adverse effects in Alecensa is 80%
• by Lee, Hye-Kyung Oct 6, 2022 06:05am

• Policy
• MFDS prepares clinical trial guidelines for COVID-19 drugs
• by Lee, Hye-Kyung Oct 6, 2022 06:05am

• Policy
• Data for reevaluation to be submitted from the 24th
• by Lee, Tak-Sun Oct 5, 2022 06:11am

• Policy
• Pfizer Corona vaccine passed a verification advisory group
• by Lee, Hye-Kyung Oct 5, 2022 06:10am

• Policy
• Post-marketing surveillance of breast cancer drug Kadcyla
• by Lee, Hye-Kyung Oct 4, 2022 06:07am

• Policy
• The price of Zerbaxa is listed at 60,098 won
• by Kim, Jung-Ju Oct 4, 2022 06:07am

• Policy
• Strengthen the guarantee of 21 new drug by the third quarter
• by Kim, Jung-Ju Sep 30, 2022 05:53am